Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related?

Ramalho, Diogo and Araújo, André and Rocha, Gustavo and Duarte-Ribeiro, Filipa (2021) Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related? European Journal of Case Reports in Internal Medicine, 8 (12). pp. 1-5. ISSN 2284-2594

3099-Article Text-26427-1-10-20211229.pdf - Published Version

Download (295kB) | Preview
Official URL:


Pituitary adenomas are the most common cause of hypopituitarism associated with pituitary enlargement, but other aetiologies have been emerging, namely immune checkpoint inhibitor-induced hypophysitis (ipilimumab, nivolumab and pembrolizumab). Secukinumab is a recently approved human monoclonal antibody used for the treatment of psoriasis, with no know reported cases of hypophysitis. We describe a challenging case of panhypopituitarism in a patient with a pituitary incidentaloma and a temporal relationship between secukinumab initiation and the manifestation of clinical features suggestive of hypopituitarism. In such intricate work-up, the differential diagnoses should be carefully considered, taking into account the therapeutic and prognostic implications.

Item Type: Article
Uncontrolled Keywords: Pituitary neoplasms, hypophysitis, hypopituitarism, secukinumab
Subjects: 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici)
Depositing User: Marina Spanti
Date Deposited: 15 Mar 2022 16:51
Last Modified: 15 Mar 2022 16:51

Actions (login required)

View Item View Item